Henry M. Dunnenberger

5.5k total citations · 4 hit papers
47 papers, 3.5k citations indexed

About

Henry M. Dunnenberger is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Genetics. According to data from OpenAlex, Henry M. Dunnenberger has authored 47 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pharmacology, 22 papers in Pediatrics, Perinatology and Child Health and 17 papers in Genetics. Recurrent topics in Henry M. Dunnenberger's work include Pharmacogenetics and Drug Metabolism (28 papers), Pharmaceutical studies and practices (18 papers) and Genomics and Rare Diseases (9 papers). Henry M. Dunnenberger is often cited by papers focused on Pharmacogenetics and Drug Metabolism (28 papers), Pharmaceutical studies and practices (18 papers) and Genomics and Rare Diseases (9 papers). Henry M. Dunnenberger collaborates with scholars based in United States, Canada and United Kingdom. Henry M. Dunnenberger's co-authors include Teri E. Klein, Kelly E. Caudle, Andrea Gaedigk, Kristine R. Crews, James M. Hoffman, Michelle Whirl‐Carrillo, Todd C. Skaar, Danny D. Shen, Mary V. Relling and John T. Callaghan and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, The Annual Review of Pharmacology and Toxicology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Henry M. Dunnenberger

44 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

2014 453 citations Andrea Gaedigk, Henry M. Dunnenberger et al. Clinical Pharmacology & Therapeutics profile →
Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

2016 450 citations Katrin Sangkuhl, Kazutaka Shimoda et al. Clinical Pharmacology & Therapeutics profile →
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

2016 354 citations Kelly E. Caudle, Henry M. Dunnenberger et al. profile →
Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers

2014 345 citations Henry M. Dunnenberger, James M. Hoffman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Henry M. Dunnenberger United States	22	2.2k	1.3k	607	566	444	47	3.5k
Larisa H. Cavallari United States	40	3.1k 1.4×	1.0k 0.8×	710 1.2×	593 1.0×	685 1.5×	198	5.3k
Cyrine E. Haidar United States	19	1.6k 0.7×	948 0.7×	470 0.8×	248 0.4×	371 0.8×	34	2.5k
Kelly E. Caudle United States	32	3.1k 1.4×	1.7k 1.4×	931 1.5×	786 1.4×	924 2.1×	61	5.5k
Jesse J. Swen Netherlands	39	3.0k 1.3×	1.4k 1.1×	866 1.4×	706 1.2×	1.3k 3.0×	164	5.9k
Andrea Jorgensen United Kingdom	32	1.4k 0.6×	488 0.4×	345 0.6×	629 1.1×	468 1.1×	107	3.7k
JS Leeder United States	10	1.3k 0.6×	904 0.7×	245 0.4×	386 0.7×	281 0.6×	10	2.3k
C. Michael Stein United States	36	1.6k 0.7×	571 0.4×	349 0.6×	626 1.1×	1.0k 2.4×	68	7.0k
Vera H.M. Deneer Netherlands	31	1.1k 0.5×	562 0.4×	222 0.4×	730 1.3×	465 1.0×	88	4.5k
Laura B. Ramsey United States	29	763 0.3×	832 0.6×	284 0.5×	300 0.5×	604 1.4×	105	3.1k
Ron HN van Schaik Netherlands	31	1.2k 0.6×	941 0.7×	403 0.7×	260 0.5×	583 1.3×	92	3.2k

Countries citing papers authored by Henry M. Dunnenberger

Since Specialization

Citations

This map shows the geographic impact of Henry M. Dunnenberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henry M. Dunnenberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henry M. Dunnenberger more than expected).

Fields of papers citing papers by Henry M. Dunnenberger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Henry M. Dunnenberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henry M. Dunnenberger. The network helps show where Henry M. Dunnenberger may publish in the future.

Co-authorship network of co-authors of Henry M. Dunnenberger

This figure shows the co-authorship network connecting the top 25 collaborators of Henry M. Dunnenberger. A scholar is included among the top collaborators of Henry M. Dunnenberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Henry M. Dunnenberger. Henry M. Dunnenberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Billings, Liana K., Zhuqing Shi, Jun Wei, et al.. (2023). Utility of Polygenic Scores for Differentiating Diabetes Diagnosis Among Patients With Atypical Phenotypes of Diabetes. The Journal of Clinical Endocrinology & Metabolism. 109(1). 107–113. 4 indexed citations

Wixson, Richard L., et al.. (2023). Pain and Opioid use Following Total Knee Arthroplasty: Psycho-Social Factors are More Predictive Than Pharmacogenomics. The Journal of Arthroplasty. 39(5). 1214–1219. 3 indexed citations

Wake, Dyson T., et al.. (2022). Pharmacogenomics of Medications Given Via Nonconventional Administration Routes: A Scoping Review. Pharmacogenomics. 23(17). 933–948. 1 indexed citations

Wake, Dyson T., et al.. (2021). Synthesis of Major Pharmacogenomics Pretest Counseling Themes: A Multisite Comparison. Pharmacogenomics. 22(3). 165–176. 10 indexed citations

Gammal, Roseann S., et al.. (2021). The pharmacist's responsibility to ensure appropriate use of direct‐to‐consumer genetic testing. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 4(5). 652–658. 7 indexed citations

Lemke, Amy A., Laura M. Amendola, Jennifer Thompson, et al.. (2021). Patient-Reported Outcomes and Experiences with Population Genetic Testing Offered Through a Primary Care Network. Genetic Testing and Molecular Biomarkers. 25(2). 152–160. 20 indexed citations

Luzum, Jasmine A., Natasha Petry, Annette K. Taylor, et al.. (2021). Moving Pharmacogenetics Into Practice: It’s All About the Evidence!. Clinical Pharmacology & Therapeutics. 110(3). 649–661. 40 indexed citations

David, Sean P., et al.. (2021). Implementing Primary Care Mediated Population Genetic Screening Within an Integrated Health System. The Journal of the American Board of Family Medicine. 34(4). 861–865. 20 indexed citations

Wake, Dyson T., D. Max Smith, Sadaf Kazi, & Henry M. Dunnenberger. (2021). Pharmacogenomic Clinical Decision Support: A Review, How‐to Guide, and Future Vision. Clinical Pharmacology & Therapeutics. 112(1). 44–57. 43 indexed citations

10.

Lemke, Amy A., Laura M. Amendola, Kristine Kuchta, et al.. (2020). Primary Care Physician Experiences with Integrated Population-Scale Genetic Testing: A Mixed-Methods Assessment. Journal of Personalized Medicine. 10(4). 165–165. 26 indexed citations

11.

Whirl‐Carrillo, Michelle, Katrin Sangkuhl, Philip E. Empey, et al.. (2020). Variant Interpretation in Current Pharmacogenetic Testing. Journal of Personalized Medicine. 10(4). 204–204. 7 indexed citations

12.

Helseth, Donald L., Kamalakar Gulukota, Nicholas Miller, et al.. (2020). Flype: Software for enabling personalized medicine. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 187(1). 37–47. 6 indexed citations

13.

Hicks, J. Kevin, Christina L. Aquilante, Henry M. Dunnenberger, et al.. (2019). Precision pharmacotherapy: Integrating pharmacogenomics into clinical pharmacy practice. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 2(3). 303–313. 54 indexed citations

14.

Wake, Dyson T., et al.. (2019). Pharmacogenomics. Medical Clinics of North America. 103(6). 977–990. 35 indexed citations

15.

Phillips, Elizabeth J., Chonlaphat Sukasem, Michelle Whirl‐Carrillo, et al.. (2018). Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clinical Pharmacology & Therapeutics. 103(4). 574–581. 182 indexed citations

16.

Patel, Jai N., Lauren Allison Wiebe, Henry M. Dunnenberger, & Howard L. McLeod. (2018). Value of Supportive Care Pharmacogenomics in Oncology Practice. The Oncologist. 23(8). 956–964. 19 indexed citations

17.

Lemke, Amy A., Peter J. Hulick, Dyson T. Wake, et al.. (2018). Patient Perspectives Following Pharmacogenomics Results Disclosure in an Integrated Health System. Pharmacogenomics. 19(4). 321–331. 39 indexed citations

18.

Hicks, J. Kevin, Katrin Sangkuhl, Jesse J. Swen, et al.. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Data Archiving and Networked Services (DANS). 57 indexed citations

19.

Hicks, J. Kevin, Henry M. Dunnenberger, Karl F. Gumpper, Cyrine E. Haidar, & James M. Hoffman. (2016). Integrating pharmacogenomics into electronic health records with clinical decision support. American Journal of Health-System Pharmacy. 73(23). 1967–1976. 123 indexed citations

20.

Mikkelsen, Torben Stamm, Caroline F. Thorn, Jun J. Yang, et al.. (2011). PharmGKB summary. Pharmacogenetics and Genomics. 21(10). 679–686. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact